PAXIL CR (paroxetine hydrochloride) by Aurobindo Pharma is (mdd), panic disorder (pd), social anxiety disorder (sad), and premenstrual dysphoric disorder (pmdd) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-ht). First approved in 1999.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
PAXIL CR is an extended-release oral tablet formulation of paroxetine hydrochloride, a selective serotonin reuptake inhibitor (SSRI) approved for major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder. It works by inhibiting the neuronal reuptake of serotonin (5-HT) in the central nervous system, thereby potentiating serotonergic activity.
Product is approaching loss of exclusivity with modest Part D spending, indicating a mature market with contracting commercial operations and reduced team expansion opportunities.
(MDD), panic disorder (PD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-HT).
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Paxil CR Bioequivalence Study Brazil - Fed Administration
Paxil CR Bioequivalence Study Brazil
PAXIL CR Bioequivalence Study
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)
Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions
Worked on PAXIL CR at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and a product approaching loss of exclusivity, PAXIL CR offers limited career growth opportunities and represents a consolidation/sunset phase rather than expansion. Professionals should view assignments to this product as specialized brand management experience in mature market maintenance rather than as a launching pad for advancement.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo